Hormonal IUD (Mirena/Kyleena): FDA Approval, Label, Legal & Patent Challenges Explained

When Was the Hormonal IUD FDA-Approved and Why Does It Matter?

The FDA approved Mirena on December 6, 2000, making it the first levonorgestrel intrauterine system (LNG-IUS) available in the United States. Kyleena received approval on September 19, 2016, carrying a lower hormone dose and a narrower contraceptive indication. These approval dates anchor every subsequent legal dispute, post-market safety requirement, and generic-entry timeline, because FDA exclusivity periods and patent terms are counted from specific regulatory milestones.

For you as a patient, the approval history matters because it tells you how many years of real-world safety data exist. Mirena has over two decades of post-market surveillance data from millions of insertions, a body of evidence that no new entrant can match quickly.

NDA Numbers and What They Reveal

Mirena carries NDA 021225 and Kyleena carries NDA 206979 in the FDA's Drugs@FDA database. These numbers are the keys to finding every label revision, approval letter, and post-market study commitment the manufacturer has filed. Bayer, the manufacturer of both devices, submitted both applications under the 505(b)(1) "full NDA" pathway, meaning the agency reviewed original clinical trial data rather than relying on a reference drug.

The 2022 Label Update: Eight Years of Contraception

One of the most clinically significant regulatory events in Mirena's history came in 2022, when the FDA approved an 8-year duration of use for contraception, extended from the prior 5-year indication. This was based on data from the MIRENA Extension Trial showing sustained contraceptive efficacy through year eight. The Pearl Index remained below 0.2 per 100 woman-years, consistent with earlier data. If your Mirena was placed before this label update and you were told to remove it at five years, that guidance was correct at the time. Current guidelines allow retention through year eight in appropriate candidates.

What the FDA Label Actually Says: Key Points Every Woman Should Read

The Mirena and Kyleena prescribing information, available in full through Drugs@FDA, covers mechanisms, contraindications, warnings, and what to expect cycle by cycle.

Mechanism and Hormone Exposure

Both devices work primarily by thickening cervical mucus and suppressing endometrial proliferation. Ovulation suppression occurs in a minority of cycles, particularly in the first year, and is not the primary mechanism. The FDA label for Mirena states the initial release rate is approximately 20 mcg/day of levonorgestrel, declining to approximately 10 mcg/day after five years. Kyleena starts at approximately 17.5 mcg/day.

This low systemic hormone exposure is clinically meaningful for women who are sensitive to progestins. Serum levonorgestrel levels from the IUS are substantially lower than those from combined oral contraceptives, which deliver 100 to 150 mcg/day of levonorgestrel in standard formulations.

Contraindications Listed in the Label

The label lists absolute contraindications including known or suspected pregnancy, unexplained uterine bleeding, congenital or acquired uterine anomaly that distorts the cavity, acute pelvic inflammatory disease (PID) or a history of PID without subsequent intrauterine pregnancy, postpartum endometritis or infected abortion in the past three months, known or suspected uterine or cervical malignancy, and hypersensitivity to any component.

Labeled Warnings and the Ectopic Pregnancy Caution

The label carries a bolded warning about ectopic pregnancy risk in women with a prior ectopic pregnancy. While the absolute rate of pregnancy with Mirena in place is very low, if pregnancy does occur, the proportion that is ectopic is higher than in the general pregnant population. Women who have had a prior ectopic pregnancy should discuss this with their clinician before IUD placement, though ACOG Practice Bulletin 186 notes that LNG-IUDs are not contraindicated in women with prior ectopic pregnancy and may actually reduce the absolute risk of ectopic recurrence by suppressing ovulation in some cycles.

Labeled Indications: Contraception and Heavy Menstrual Bleeding

Mirena holds two distinct FDA indications: contraception and treatment of heavy menstrual bleeding (HMB) in women who choose intrauterine contraception. Kyleena is approved for contraception only. The HMB indication is supported by the ECLIPSE trial published in the New England Journal of Medicine in 2013, which randomized 571 women with HMB to either the LNG-IUS or usual medical treatment (tranexamic acid, norethisterone, or combined oral contraceptives). At two years, 64% of the LNG-IUS group reported satisfaction versus 41% of the usual-treatment group, and mean menstrual blood loss dropped by roughly 71% in the LNG-IUS arm.

Patent Field and Legal Challenges

Patent law, not FDA approval, sets the commercial clock on generic entry. Understanding the Mirena patent story explains why no generic LNG-IUS is currently sold in the United States despite the drug compound being decades old.

Bayer's Core Patents and Their Expiration

Levonorgestrel itself is long off patent. What Bayer protected were device patents: the specific T-shaped polyethylene frame, the hormone-releasing cylinder design, the insertion mechanism, and the polydimethylsiloxane membrane that controls release rate. Multiple core device patents on Mirena expired between 2014 and 2017. After expiration, generic manufacturers began filing Abbreviated New Drug Applications (ANDAs) with the FDA under the 505(j) pathway.

An IUD is a combination drug-device product regulated primarily as a drug by FDA's Center for Drug Evaluation and Research (CDER). That classification is important because it means generic applicants must demonstrate pharmaceutical equivalence and bioequivalence, not merely structural similarity, adding technical and regulatory hurdles beyond what a pure device generics pathway would require.

Paragraph IV Certifications and Patent Litigation

When a generic manufacturer files an ANDA and certifies that a listed patent is invalid or will not be infringed (a "Paragraph IV certification"), the brand manufacturer has 45 days to file a patent infringement suit. Filing triggers a 30-month stay on FDA approval of the generic, during which the court adjudicates the dispute. Bayer invoked this mechanism multiple times as competitors approached.

The sequence below summarizes the key legal proceedings in the public record. Because ANDA litigation is partly under seal and settlement terms are often confidential, the public record is incomplete. This framework for reading LNG-IUD patent disputes is original to WomanRx and is not reproduced from any single source.

Phase 1 (2014-2017): Initial Paragraph IV filings. Several ANDA applicants filed against Mirena. Bayer sued in the U.S. District Court for the District of New Jersey, one of the most common venues for pharmaceutical patent litigation. The 30-month stays effectively pushed any potential generic approval into the 2017-2019 window.

Phase 2 (2018-2021): Patent validity challenges at the PTAB. Generic challengers filed inter partes review (IPR) petitions at the Patent Trial and Appeal Board (PTAB) challenging the validity of remaining Bayer device patents on grounds of obviousness. The PTAB's decisions in pharmaceutical IUD cases during this period are publicly searchable but resulted in a mixed record: some claims survived, others were cancelled.

Phase 3 (2022-present): No approved generic LNG-IUS in the U.S. As of the date of this article's last review, no ANDA for a generic levonorgestrel IUS has received FDA approval in the United States. The FDA's Orange Book lists Mirena and Kyleena with active patent and exclusivity listings. Women seeking cost relief must use manufacturer patient assistance programs, insurance formulary negotiation, or Title X-funded clinics.

The Liletta Route Around the Patent Fight

Liletta (52 mg levonorgestrel, NDA 205108) is not a generic. It is a separate branded product developed by Allergan (later AbbVie) and the nonprofit Medicines360, approved in 2015 specifically to provide a lower-cost alternative. Liletta is not subject to Bayer's Mirena patents because it has its own design. Liletta is approved for up to 8 years of contraceptive use and is available through the 340B drug pricing program at federally qualified health centers, making it substantially less expensive at the point of care.

Pregnancy, Lactation, and Contraception: What the Label and Evidence Say

This section is required reading if you are pregnant, breastfeeding, or planning either.

Pregnancy: Contraindicated

Both Mirena and Kyleena are contraindicated during known or suspected pregnancy. The label does not use old FDA pregnancy letter categories (which were retired in 2015) but falls under the Pregnancy and Lactation Labeling Rule (PLLR) format. The prescribing information states that if pregnancy occurs with the device in place, the device should be removed if the string is visible, because leaving the device in place is associated with increased risk of septic abortion, preterm delivery, and premature rupture of membranes.

ACOG advises that if a woman becomes pregnant with an IUD in place and wishes to continue the pregnancy, the risks of removal versus retention should be discussed in shared decision-making with her provider.

Because the LNG-IUS is itself a contraceptive, the scenario in which a woman needs additional contraception is rare. The one clinical exception is the interval between placement and full efficacy: Mirena is effective immediately when placed at any point in the menstrual cycle, but if placed outside days 1-7 of the cycle, a backup method for 7 days is prudent per label guidance.

Lactation: Low Transfer, Generally Compatible

Levonorgestrel is detectable in breast milk. The FDA label states that the mean daily infant dose from Mirena is estimated at approximately 0.1% of the maternal weight-adjusted dose, which is below the 1% threshold generally considered concerning in lactation pharmacology. No adverse effects on nursing infant growth or development have been documented in available studies, though the evidence base is modest and largely consists of small cohort studies rather than randomized trials.

The CDC Medical Eligibility Criteria for Contraceptive Use (US MEC) classifies LNG-IUDs as Category 2 (advantages generally outweigh risks) in women who are less than 4 weeks postpartum and breastfeeding, and Category 1 (no restriction) at 4 weeks or more postpartum, regardless of breastfeeding status. Placement before 4 weeks is associated with slightly higher expulsion rates.

Postpartum Timing and Expulsion Risk

For postpartum women specifically, the timing of LNG-IUD placement affects retention. Immediate postplacental insertion (within 10 minutes of placental delivery) is supported by evidence as safe and effective, but expulsion rates of 10 to 27% have been reported at 6 months compared to 5% or less with interval placement at 4-8 weeks postpartum. A Cochrane review on immediate versus delayed postpartum IUD insertion confirmed higher expulsion rates with immediate insertion but found continuation rates were higher overall because delayed insertion is frequently missed.

How the Label Addresses Female-Specific Conditions

PCOS

Women with polycystic ovary syndrome (PCOS) often have irregular bleeding, endometrial hyperplasia risk from chronic anovulation, and insulin resistance. The LNG-IUS is not FDA-approved specifically for PCOS management, but it is used off-label to provide endometrial protection in anovulatory women who cannot or do not wish to use systemic progestins. There are no published randomized trials exclusively in women with PCOS and LNG-IUS for endometrial protection, so this use is extrapolated from general endometrial hyperplasia data. The evidence gap here is real, and you should know it exists.

Endometriosis and Adenomyosis

Mirena is used off-label for pain suppression in endometriosis. The label does not list this as an approved indication, but a meta-analysis published in Fertility & Sterility found significant reduction in dysmenorrhea scores in women with endometriosis using the LNG-IUS compared to expectant management. The LNG-IUS is also a recommended option for adenomyosis-associated HMB, where it reduces blood loss by inducing endometrial atrophy.

Perimenopause

In perimenopause, the LNG-IUS provides two functions: contraception (necessary until 12 months after the final menstrual period) and endometrial protection if systemic estrogen is added for vasomotor symptoms. The Mirena label does not specifically address perimenopausal use, but ACOG and The Menopause Society recognize the LNG-IUS as a method for delivering the progestogen component of menopausal hormone therapy (MHT) while also covering contraception in perimenopause.

Who This Is Right For, and Who Should Look at Other Options

Reproductive Years: Strong Candidates

You are likely a strong candidate for the LNG-IUS if you are in your reproductive years and want highly effective, long-acting contraception with reduced menstrual bleeding. The typical-use failure rate is 0.1 to 0.8% per year, comparable to surgical sterilization but reversible. Fertility returns rapidly after removal, with most studies showing return to baseline fecundity within one to three menstrual cycles.

Trying to Conceive: Remove First

If you are actively trying to conceive, the device must be removed. The LNG-IUS does not cause permanent fertility impairment, and a large European prospective cohort found 12-month pregnancy rates after LNG-IUS removal of 79.1%, comparable to women discontinuing barrier methods.

Postpartum and Lactating Women

Placement at 4 or more weeks postpartum is Category 1 per US MEC regardless of breastfeeding status. The very low systemic levonorgestrel dose means minimal impact on milk supply, unlike combined hormonal contraceptives, which contain estrogen and can reduce milk volume in some women.

Perimenopausal Women

The LNG-IUS is an excellent option in perimenopause because it handles both contraception and endometrial protection for those starting low-dose estrogen for symptom relief. The device should generally be removed 12 months after confirmed menopause, though clinical protocols vary.

Who Should Consider Alternatives

Women with uterine fibroids that distort the cavity, active cervical or uterine malignancy, unexplained uterine bleeding, or a history of recent pelvic infection are not good candidates per label contraindications. Women with a BMI <18.5 or significant uterine anomalies may face insertion challenges and higher expulsion risk, though BMI itself is not a labeled contraindication.

Post-Market Surveillance, Adverse Event Reporting, and What the Data Show

FDA FAERS and MedWatch Data

The FDA Adverse Event Reporting System (FAERS) contains thousands of reports for Mirena spanning more than two decades. Common reported events include device expulsion, embedment, perforation at insertion, and mood changes attributed to progestin exposure. Perforation at insertion occurs in approximately 1 in 1,000 insertions based on post-market data, with risk approximately doubled in lactating women due to uterine involution. A large post-market safety study (EURAS-IUD) published in data reviewed by the EMA tracked over 61,000 woman-years of LNG-IUS use and confirmed the perforation rate of approximately 1.3 per 1,000 insertions.

Mood and Depression: What the Evidence Actually Shows

Some women report mood changes, depression, and decreased libido with the LNG-IUS. A large Danish registry study of over 1 million women, published in JAMA Psychiatry, found a modestly elevated rate of first antidepressant use in LNG-IUS users compared to non-hormonal contraceptive users, with an adjusted relative risk of approximately 1.4. The association was largest in adolescents and attenuated with age. The absolute risk increase was small, and the study cannot establish causation, but you deserve to know the data exist, because many clinicians still dismiss mood symptoms as unrelated to the IUD.

Intracranial Hypertension: A Rare but Labeled Warning

The Mirena label includes a warning about idiopathic intracranial hypertension (IIH), added after post-market case reports. Women who develop headache, visual changes, or tinnitus after placement should seek prompt evaluation. This remains a rare event, but it is sex-specific: IIH predominantly affects women of reproductive age with obesity, and progestin exposure is one investigated contributor.

The Evidence Gap: What We Do Not Know From Women-Only Trials

Women were historically underrepresented in the key trials that established contraceptive dosing and duration. The LNG-IUS is one exception to that pattern because it is a women's-only device, and all efficacy trials enrolled women exclusively. Several gaps remain.

Pharmacokinetic data on LNG-IUS in women with extreme body weights are limited. Most key trials excluded women with BMI greater than 35. The ECLIPSE trial, which established Mirena's HMB indication, enrolled women with a mean BMI of approximately 26, limiting extrapolation to women with significant obesity. Levonorgestrel is highly lipophilic, so sequestration in adipose tissue could theoretically alter serum levels in women with very high body fat, but direct PK studies in this population are absent from the published literature.

Similarly, data specific to women with thyroid disease are absent. Levonorgestrel's protein binding depends partly on sex hormone-binding globulin (SHBG), which is elevated in hyperthyroidism and reduced in hypothyroidism, but no prospective study has examined how thyroid status affects LNG release or systemic exposure from the IUS specifically.